Objectives
The objective of the ASET-JAPAN study is to investigate feasibility and safety of single antiplatelet therapy with low-dose prasugrel immediately after PCI with optimal everolimus-eluting platinum chromium stent implantation in Japanese population.
Study design
The ASET Japan Pilot study is a multicenter, single arm, open-label trial of single antiplatelet therapy with low dose prasugrel for patients undergoing successful.
Endpoints
For each endpoint
- Primary Ischemic Endpoint
- Primary Bleeding Endpoint
- Secondary endpoints (evaluated at each follow-up visit/contact)
News
-
2021.12.22
Start case registration(Phase2)
Case registration for Phase2 has started.
Participating Facilities
Principle Investigators
-
Yukio Ozaki
Fujita Health University Okazaki Medical Center
-
Kengo Tanabe
Mitsui Memorial Hospital
-
Takashi Muramatsu
Fujita Health University
-
Patrick W. Serruys
National University of Ireland Galway (NUIG)
-
Yoshinobu Onuma
National University of Ireland Galway (NUIG)
Investigators
-
Ken Kozuma
Teikyo University Hospital
-
Yoshihiro Morino
Iwate Medical University Hospital
-
Gaku Nakazawa
Kindai University Hospital
-
Takayuki Okamura
Yamaguchi University Hospital
-
Hiroki Tateishi
Yamaguchi University Hospital
-
Yosuke Miyazaki
Yamaguchi University Hospital
-
Yuki Ishibashi
St. Marianna University Hospital
-
Hideyuki Kawashima
Teikyo University Hospital
-
Taku Asano
St Luke’s international hospital
-
Shimpei Nakatani
JCHO Hoshigaoka Medical Center
-
Kuniaki Takahashi
Kindai University Hospital
-
Yuki Katagiri
Sapporo Higashi Tokushukai Hospital
-
Kogame Norihiro
Toho University Ohashi Medical Center
Patients Enrolled109
If you are interest in the ASET study and would like to joint our study,
please contact with us through E-mail without any hesitation.